Microneedle and Photodynamic Therapy for Oral Leukoplakia
Objective
To see if microneedle treatment can make photodynamic therapy (PDT) more effective and safer for oral leukoplakia.
Methods
A clinical trial was done with patients diagnosed with oral leukoplakia. They were split into two groups:
- Control Group: Received standard ALA-PDT.
- Experimental Group: Received microneedle treatment with lidocaine before ALA-PDT.
We recorded how each group responded, measured the size of the lesions, and evaluated treatment effectiveness. Pain levels post-treatment were assessed using a visual analogue scale.
Results
A total of 30 patients participated:
- Experimental Group: 11 patients
- Control Group: 19 patients
Findings:
- Complete remission: 45.5% (experimental) vs. 36.8% (control)
- Partial remission: 54.5% (experimental) vs. 57.9% (control)
- No remission: 0% (experimental) vs. 5% (control)
Significant differences were noted in:
- Treatment time: 9.05 minutes/cm2 (experimental) vs. 21.38 minutes/cm2 (control)
- Number of sessions: 2.36 (experimental) vs. 3.58 (control)
Pain scores were similar for both groups, and microneedle treatment did not increase adverse effects.
Conclusion
Microneedle pretreatment with ALA-PDT effectively treats oral leukoplakia, reduces treatment time, lowers the number of visits, and saves costs.
Enhancing Clinical Practices
Clinical trials are essential for developing safe treatments. Our AI platform, DocSym, brings together ICD-11 standards, clinical protocols, and research for easier access by clinicians.
Streamlining Healthcare
In today’s healthcare, efficiency is vital. Our mobile apps help with:
- Scheduling appointments
- Monitoring treatments
- Telemedicine services
Using AI improves workflows, enhances patient outcomes, and reduces paperwork. Learn more at aidevmd.com.
